Mallinckrodt agreed to settle allegations that its subsidiary Questcor Pharmaceuticals bribed physicians to over-prescribe its multiple sclerosis drug H.P. Acthar Gel (repository corticotropin).
The U.S. Attorney’s Office for the Eastern District of Pennsylvania accused Questcor — which Mallinckrodt acquired in 2014 — of bribing doctors with lavish dinners and entertainment to prescribe the drug between 2009 and 2013.
The allegations against Mallinckrodt stem from whistleblower suits filed in 2012 and 2013. The whistleblowers will receive almost $3 million of the settlement.